Zobrazeno 1 - 10
of 26
pro vyhledávání: '"KENJI HANYU"'
Autor:
Takashi Matsuki, Daisuke Kawakita, Hideaki Takahashi, Takuro Okada, Akihiro Sakai, Yushi Ueki, Hiroshi Tsuge, Kenji Hanyu, Kaho Momiyama, Ryusuke Shodo, Mayu Yamauchi, Yukiko Asako, Hideaki Hirai, Toshitaka Nagao, Yuichiro Tada
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Although immune checkpoint inhibitors (ICIs) are effective in some patients with salivary gland carcinoma (SGC), biomarkers which predict the efficacy and prognosis of SGC patients treated with pembrolizumab have not been identified. We cond
Externí odkaz:
https://doaj.org/article/b5b7acb4c83f4a13bea2ec729ee7a8c0
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 169-174 (2024)
Introduction: Head and neck photoimmunotherapy (HN-PIT) has been conditionally approved by the Japanese government for the treatment of unresectable locally advanced or locally recurrent head and neck cancer since January 2021. HN-PIT makes local tre
Externí odkaz:
https://doaj.org/article/71e0d00c0eb64131919f3ebe9d859e20
Autor:
Kouki Miura, Daisuke Kawakita, Isao Oze, Motoyuki Suzuki, Masashi Sugasawa, Kazuhira Endo, Tomohiro Sakashita, Shinichi Ohba, Mikio Suzuki, Akihiro Shiotani, Naoyuki Kohno, Takashi Maruo, Chiaki Suzuki, Takehiro Iki, Nao Hiwatashi, Fumihiko Matsumoto, Kenya Kobayashi, Minoru Toyoda, Kenji Hanyu, Yusuke Koide, Yoshiko Murakami, Yasuhisa Hasegawa
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract Prophylactic elective neck dissection (ND) with navigation surgery using radioisotope-based sentinel lymph node biopsy (SLNB) is non-inferior to elective ND in terms of survival but has an advantage in postoperative functional disability. We
Externí odkaz:
https://doaj.org/article/5f4f63ffba7d441da42feea4deb05d13
Autor:
TAKURO OKADA, CHIHIRO FUSHIMI, TAKASHI MATSUKI, KUNIHIKO TOKASHIKI, HIDEAKI TAKAHASHI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KENJI HANYU, TAKUMA KISHIDA, TATSUYA ITO, GAI YAMASHITA, TATSUO MASUBUCHI, YUICHIRO TADA, KOKI MIURA, GO OMURA, TAKU YAMASHITA, NOBUHIKO ORIDATE, KIYOAKI TSUKAHARA
Publikováno v:
Anticancer Research. 43:2717-2724
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c51a71d153e2a5a6bd0991ba6fe9d92b
https://doi.org/10.21873/anticanres.16438
https://doi.org/10.21873/anticanres.16438
Autor:
TAKURO OKADA, CHIHIRO FUSHIMI, TAKASHI MATSUKI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KUNIHIKO TOKASHIKI, TAKUMA KISHIDA, TATSUYA ITO, GAI YAMASHITA, YUSUKE AIHARA, KENJI HANYU, YUKIOMI KUSHIHASHI, TATSUO MASUBUCHI, YUICHIRO TADA, KOUKI MIURA, YUKI HARADA, KAHO MOMIYAMA, TAKU YAMASHITA, GO OMURA, HIDEAKI TAKAHASHI, NOBUHIKO ORIDATE, KIYOAKI TSUKAHARA
Publikováno v:
Anticancer Research. 42:1607-1613
There are no real-world comparative data of nivolumab doses of 3 mg/kg and 240 mg/body for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We investigated the efficacy and safety of nivolumab in treating recurrent/metas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be423a1d812728e74383ab8b5337273d
https://doi.org/10.21873/anticanres.15635
https://doi.org/10.21873/anticanres.15635
Autor:
Chihiro Fushimi, Yuichiro Tada, Tatsuo Masubuchi, Morio Yamazaki, Kenji Hanyu, Naruhisa Tanaka, Yukiomi Kushihashi, Mayu Yamauchi, Satomi Sugiyama, Kouki Miura
Publikováno v:
Toukeibu Gan. 48:14-20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a70b4fd724ff1e4cf874a07c7fddef4
https://doi.org/10.5981/jjhnc.48.14
https://doi.org/10.5981/jjhnc.48.14
Autor:
Yukiomi Kushihashi, Chihiro Fushimi, Tatsuo Masubuchi, Kenji Hanyu, Yuichiro Tada, Koki Miura
Publikováno v:
JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY. 32:1-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69180a2ff11ce20ded28776f01def3cf
https://doi.org/10.5106/jjshns.32.1
https://doi.org/10.5106/jjshns.32.1
Autor:
Yukiomi Kushihashi, Tatsuo Masubuchi, Isaku Okamoto, Chihiro Fushimi, Kenji Hanyu, Mayu Yamauchi, Yuichiro Tada, Koki Miura
Publikováno v:
International Journal of Otolaryngology and Head & Neck Surgery. 11:258-265
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49662be45a9533818d39bee40bb9daef
https://doi.org/10.4236/ijohns.2022.115027
https://doi.org/10.4236/ijohns.2022.115027
Autor:
Takayuki Yamada, Makoto Arai, Hitoshi Hirakawa, Naomi Kudo, Takashi Fujii, Kiyoaki Tsukahara, Akihiro Homma, Tomoya Yokota, Shin Kariya, Takeharu Ono, Moriyasu Yamauchi, Kenji Hanyu, Nobuya Monden, Nobuhiro Hanai, Ryuji Yasumatsu, Takahiro Asakage, Akihito Watanabe, Tsutomu Ueda, Shunji Takahashi, Koichi Omori, Takahiro Nekado, Yasushi Shimizu, Syuji Yonekura, Daisuke Sano, Tomoko Yamazaki, Mizuo Ando
Publikováno v:
International Journal of Clinical Oncology
Background We have previously reported the effectiveness and safety of nivolumab in patients with head and neck cancer (HNC) in real-world clinical practice in Japan. Here, we report long-term outcomes from this study in the overall population and su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::530fb9a875daffabe4b4c71ac27aacec
http://hdl.handle.net/2115/83677
http://hdl.handle.net/2115/83677
Autor:
TAKURO OKADA, TAKASHI MATSUKI, CHIHIRO FUSHIMI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KUNIHIKO TOKASHIKI, TATSUYA ITO, TATSUO MASUBUCHI, YUICHIRO TADA, KOUKI MIURA, KENJI HANYU, GO OMURA, HIDEKI TAKAHASHI, TAKU YAMASHITA, NOBUHIKO ORIDATE, KIYOAKI TSUKAHARA
Publikováno v:
Anticancer research. 42(10)
Nivolumab has antitumor efficacy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who relapse within 6 months after platinum-based therapy; however, the efficacy of nivolumab for platinum-sensitive R/M HNSCC has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::333752f6871449e3207fb0d28370efd2
https://pubmed.ncbi.nlm.nih.gov/36192003
https://pubmed.ncbi.nlm.nih.gov/36192003